Quoting both its CEO and executive vice president: “It’s the most important investment in the history of our Group”.
Angelini Pharma will acquire Arvelle in an all cash transaction for a total aggregate valuation of up to USD 960 million. Following customary regulatory approval, an amount of USD 610 million will be paid. Subsequently, and subject to reaching certain revenue targets, a further USD 350 million will be paid.
NautaDutilh has acted as Arvelle' s Dutch counsel since its inception in 2019 and also advised Arvelle on its Series A Investment. In that investment round Arvelle received one of the largest initial financing commitments for an European-focused biopharmaceutical company from a global syndicate of investors that include NovaQuest, LSP, BRV Capital Management, Andera Partners, and H.I.G. BioHealth Partners.